Kamar Nassim, Rischmann Pascal, Guilbeau-Frugier Céline, Sallusto Federico, Khedis Mehdi, Delisle Marie-Bernadette, Noury Didier, Fort Marylise, Rostaing Lionel
Department of Nephrology, Dialysis, and Multiorgan Transplantation, University Hospital, CHU Rangueil, Toulouse Cedex, France.
Am J Kidney Dis. 2008 Sep;52(3):591-4. doi: 10.1053/j.ajkd.2008.03.037. Epub 2008 Jun 13.
The donor organ shortage has compelled transplant centers to use organs from nontraditional sources. One example is the reuse of a previously transplanted organ, such as a kidney or liver retrieved from a brain-dead allograft recipient. For the first time, we reused a previously transplanted kidney that experienced intractable recurrent thrombotic microangiopathy (TMA) from a living allograft recipient. Within a few weeks posttransplantation, a deceased kidney allograft recipient developed intractable severe recurrent idiopathic TMA in the allograft despite intensive plasma exchanges and steroid and rituximab therapy. This required nephrectomy to cure TMA. The index recipient was believed to have a well-functioning allograft despite TMA (serum creatinine, 1.36 mg/dL [120 micromol/L]) and microalbuminuria with albumin of 1.2 g/dL [12 g/L]), and it appeared mildly damaged on biopsy examination. After donor and recipient informed consents were obtained and after approval of the French Agency of Biomedicine, the TMA allograft was reused and transplanted into a recipient whose original kidney disease was polycystic kidney disease. The retransplantation was uneventful, and at 6 months posttransplantation, the ultimate recipient's serum creatinine level was 1.06 mg/L (97 micromol/L) and albuminuria was 0.5 g/dL (5 g/L). A routine kidney biopsy showed mild glomerular lesions. After allograft nephrectomy, the donor's hematologic TMA symptoms dissipated within 10 days. We conclude that a kidney allograft with TMA recurrence can be successfully retransplanted into another recipient with excellent kidney function while still curing the first recipient of recurrent TMA. This might increase the number of kidney allografts from extended criteria donors.
供体器官短缺迫使移植中心使用非传统来源的器官。一个例子是重复使用先前移植的器官,比如从脑死亡同种异体移植受者体内获取的肾脏或肝脏。我们首次重复使用了一个先前移植的肾脏,该肾脏来自一名活体同种异体移植受者,且出现了难治性复发性血栓性微血管病(TMA)。在移植后几周内,一名已故肾脏同种异体移植受者尽管接受了强化血浆置换、类固醇和利妥昔单抗治疗,但移植肾仍出现了难治性严重复发性特发性TMA。这需要进行肾切除术来治愈TMA。尽管存在TMA(血清肌酐1.36 mg/dL [120 μmol/L])和微量白蛋白尿(白蛋白1.2 g/dL [12 g/L]),但该索引受者的移植肾被认为功能良好,活检检查显示其有轻度损伤。在获得供体和受体的知情同意书并经法国生物医学机构批准后,将发生TMA的移植肾重复使用并移植给一名原发性肾病为多囊肾病的受者。再次移植过程顺利,移植后6个月,最终受者的血清肌酐水平为1.06 mg/L(97 μmol/L),蛋白尿为0.5 g/dL(5 g/L)。常规肾脏活检显示有轻度肾小球病变。移植肾切除术后,供体的血液学TMA症状在10天内消失。我们得出结论,复发TMA的移植肾可以成功再次移植给另一名肾功能良好的受者,同时治愈第一名受者的复发性TMA。这可能会增加扩展标准供体的肾脏同种异体移植数量。